[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583753":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"The group of daGOAT model prevention","EXPERIMENTAL","Model-predicted patients at high risk (HR): Recombinant humanized anti-CD25 monoclonal antibody: 50 mg\u002Fday when the post-transplant model predicts high risk in the second week post-prediction and 25 mg\u002Fday in the fourth and sixth weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.\n\nModel-predicted patients at moderate risk (MR): Recombinant anti-CD25 humanized monoclonal antibody: 25 mg\u002Fday when the model predicts intermediate risk post-transplantation and at the 2nd, 4th, and 6th weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.\n\nModel-predicted patients at low-risk (LR): A conventional aGVHD prevention regimen only was used.",[13],"Drug: Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"erlie jiang","CONTACT","+86-15122538106","jiangerlie@ihcams.ac.cn",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"yigeng cao","+86-18622477066","caoyigeng@ihcams.ac.cn",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":40,"coordinates":41},"Point",[42,43],117.17667,39.14222,{"lat":43,"lon":42},[46],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":47},"zihua.zhang@zenithcro.com",{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100583753","phase-2-anti-cd25-rhmab-for-agvhd-prevention-in-high-risk-adults-using-the-dagoat-model-100583753",false,"NCT06880419","Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model","A Prospective, Single-arm, Historically Controlled, Single-center Study for Preventing aGVHD, Post-allogeneic HSCT, in Adults at Moderate-to-high Risk Using Recombinant Humanized Anti-CD25 Monoclonal Antibody Based on the daGOAT Model","Inclusion Criteria:\n\n1. Age ≥ 16 years, regardless of gender.\n2. Patients with hematologic disorders who are scheduled to receive allo-HSCT.\n3. Voluntarily join this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Patients who have received a second or multiple transplants.\n2. Patients who are allergic to, or intolerant of, a recombinant humanized anti-CD25 monoclonal antibody injection.\n3. Pregnant or lactating female patients or female patients who are unable to take effective contraceptive measures during the entire trial period.","ALL","16 Years",{"count":60,"type":61},174,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).",[67],"Acute Graft-versus-Host Disease","2025-08-04",{"date":70,"type":71},"2025-08-08","ACTUAL",{"date":73,"type":71},"2025-03-03",{"date":75,"type":61},"2026-12-31",{"name":5,"class":6},1]